UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift to

Zoetis (NYSE: ZTS - Get Free Report) and Urogen Pharma (NASDAQ: URGN - Get Free Report) are both hea

UroGen Pharma Ltd. has transitioned into a commercial-stage biopharma, driven by strong adoption of

Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key

PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech com

PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

BlackRock Inc. purchased a new position in Urogen Pharma (NASDAQ: URGN) in the undefined quarter, ac

The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empiric

IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical stu

Collaboration grants UroGen a research license and exclusive options to license and develop up to th

Collaboration grants UroGen a research license and exclusive options to license and develop up to th

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing inno

PRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's fi

Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises th

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a B

Urogen Pharma NASDAQ: URGN reported second-quarter 2026 revenue of $72.5 million, up from $24.2 mill

TD Cowen analyst Tara Bancroft maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the pr

UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript

Urogen Pharma (URGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Es

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.28) per share which beat the analyst co

ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter

Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET Conference Cal

ADAR1 Capital Management LLC raised its holdings in Urogen Pharma (NASDAQ: URGN) by 139.1% during th

Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the pr

UroGen Pharma is shifting NMIBC treatment from surgery to office-based chemoablative therapy with ZU

Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing inno

PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

The IND clearance enables initiation of a planned Phase 1 clinical study in patients with non-muscle

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a

This Agreement resolves the patent litigation UroGen initiated in response to Teva's submission

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a

The six-month results from UTOPIA are generally consistent with the 91.9% (95% CI: 86.9, 95.0) six-m

64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Co

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a B

Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and r

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.47) per share which beat the analyst co